The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
ACADEMIA
Alvesco Fails in COVID-19 Trial, NCGM Says It Can’t Be Recommended
Teijin Pharma’s Alvesco (ciclesonide), an inhaled corticosteroid for asthma that has been seen as a potential treatment for COVID-19, failed to demonstrate efficacy in preventing the worsening of pneumonia in a Japanese clinical trial. The National Center for Global Health…
To read the full story
Related Article
- 26 Patients Enrolled in Alvesco’s Novel Coronavirus Trial: NCGM
June 1, 2020
- Japan Plans Alvesco Clinical Trial for Coronavirus
March 24, 2020
- Japan Govt Orders 20,000 Alvesco Inhalers as Coronavirus Measure
March 11, 2020
- Alvesco Inhibits RNA Replications: NIID
March 9, 2020
- With Sudden Spotlight on Alvesco for COVID-19, Teijin Being Flooded with Inquiries
March 6, 2020
- Asthma Drug Alvesco Possibly Effective for COVID-19
March 4, 2020
ACADEMIA
- 3 Existing Drugs Show Inhibitory Effects for SARS-CoV-2 in iPSC Screening
April 8, 2021
- Tokushukai Weighs Switches from Nichi-Iko Products after Biz Suspension Order
March 15, 2021
- COVID-19 Vaccination Should Be Avoided in Patients with Severe Hypersensitivity to PEG: Allergy Society
March 3, 2021
- Thorough Medication Guidance through Regional Collaboration Important for Rybelsus: Professor
February 22, 2021
- NCGM to Initiate Clinical Study of Convalescent Plasma Therapy for COVID-19 as Early as February
January 28, 2021
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
After decades in recruitment, I say from experience that there’s a particular way to attract candidates to a given role. Do it right, and you’ll have talent chasing you. Get it wrong, and you’ll be left listening to the crickets…